Certified by Founder Lodge
Avalyn Pharma Inc.
United States - Seattle, Washington
START UP
1 Disclosed Funding Rounds $175,000,000
0 Participating Investments
-
Founded date
2022
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung disea
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| September, 28 ,2023 | Series C | $175,000,000 |
F-Prime Capital
Norwest Venture Partners
Novo Holdings
Wellington Management
T. Rowe Price
Catalio Capital Management
Rock Springs Capital
Xontogeny
Vida Ventures, LLC
Eventide Asset Management
Pivotal bioVenture Partners
Surveyor Capital
RiverVest Venture Partners
SR One Capital Management
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
